Trial Profile
A Phase III Multicentric Randomized Study of the Combination of Repeated Doses of Gemtuzumab Ozogamicin (GO) With Daunorubicin and Cytarabine Versus Daunorubicin and Cytarabine in Untreated Patients With Acute Myeloid Leukemia (AML) Aged 50-70 Years Old.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms Mylofrance 3
- 09 Feb 2021 Results of retrospective analysis assessing VOD/SOS and post-transplant outcomes in patients who received HSCT as follow-up therapy in this study, published in the Bone Marrow Transplantation.
- 19 Nov 2020 Results of the cost effective analysis of gemtuzumab ozogamicin in combination with daunorubicin and cytarabine versus daunorubicin and cytarabine alone presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 21 Jun 2020 Results of post hoc analysis from this study presented at the 25th Congress of the European Haematology Association